Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. Is Halozyme Therapeutics, Inc. (HALO) the Unstoppable Growth Stock to Invest in Now? The analyst supported the optimistic rating with the company’s growth potential and the stability of its financial prospects, citing the recent success ...